Recombinant protein · developed by Okyo Pharma
OK-101 is an investigational recombinant protein studied in Dry Eye Disease, Neuropathic Pain.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06637527 | Phase 2 | Neuropathic Pain | Terminated | OKYO |
| NCT05759208 | Phase 2 | Dry Eye Disease | Completed | OKYO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Dry Eye DiseaseNeuropathic Pain
See OKYO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
OKYO catalysts and pipeline →